肿瘤耐药 不容忽视

化疗是癌症治疗的主要策略之一。近年来随着肿瘤生物学和生物技术学的进展，很多抗肿瘤药物成功研发，极大地改善了癌症患者的生活质量和生存率。但是肿瘤的多药耐药性也随之而来．严重影响了化疗药物的疗效。本文针对发表在《临床医师肿瘤杂志》（CA Cancer J Clin）2009年第2期的一篇文章，提出抗肿瘤药物的研发与肿瘤耐药间形成一场特殊的“军备竞赛”，在我们研发抗肿瘤药物时还必须深刻认识到肿瘤多药耐药性的机制，期望能够引起同行的争鸣。

Multidrug resistance of novel anticancer drugs cannot be ignored

Chemotherapy has been one of the main therapeutic strategies in cancer treatment. And several decades of preclinical progress in cancer biology and biotechnology have recently led to successful development of several biological agents that substantially improve survival and quality of life for some patients. However, resistance has followed as a faithful shadow and ineffectiveness of anticancer drugs is frequently observed in cancer chemotherapy. The resistance of tumor cells to various cytotoxic drugs is defined as multidrug resistance （MDR）. In this paper we proposed that development of novel agents for cancer therapy and the cancer MDR promote an evolutionary arms race. In this battlefield, we have to emphasize the knowledge of mechanisms of MDR in research of novel anticancer drugs. It is anticipated that contention may be aroused among the investigators.